Pain control in cancer: Recent findings and trends

Annals of Oncology

Volumn 18, Issue SUPPL. 9, 2007, Pages

  Schrijvers, D ^a  

^a ZiekenhuisNetwerk Antwerpen   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CODEINE; DELTA OPIATE RECEPTOR AGONIST; DEXTROMETHORPHAN; DRONABINOL; FENTANYL; HYDROMORPHONE; KAPPA OPIATE RECEPTOR AGONIST; KETAMINE; LEVONANTRADOL; METHADONE; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; NOCICEPTIN; OPIATE; OPIATE ANTAGONIST; OXYCODONE; STEROID; TACHYKININ RECEPTOR ANTAGONIST; TRAMADOL; UNINDEXED DRUG; ANALGESIC AGENT;

ADRENERGIC ACTIVITY; ANAMNESIS; ATAXIA; AUTONOMIC DYSFUNCTION; BLURRED VISION; CANCER PAIN; CLINICAL EXAMINATION; CONFERENCE PAPER; CONSTIPATION; DISORIENTATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; EFFERENT NERVE; HUMAN; HYPERALGESIA; MEMORY DISORDER; MENTAL DISEASE; MOOD CHANGE; NEUROENDOCRINE DISEASE; NEUROPATHIC PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SLURRED SPEECH; THOUGHT DISORDER; TREND STUDY; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; ADJUVANT CHEMOTHERAPY; NEOPLASM; PAIN; QUESTIONNAIRE; REVIEW;

ANALGESICS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASMS; PAIN; QUESTIONNAIRES;

EID: 36049004945     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm292     Document Type: Conference Paper

References (10)

1. World Health Organization. Cancer Pain Relief with a Guide to Opioid Availability. Geneva: World Health Organization 1996.
2. Giordano J. The Neurobiology of Nociceptive and Anti-nociceptive Systems. Pain Physician 2005; 8: 277-290.
3. Zadina JE, Martin-Schild S, Gerall AA et al. Endomorphins: Novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density. Ann NY Acad Sci 1999; 897: 136-144.
4. Gilron I, Watson CP, Cahill CM et al. Neuropathic pain: A practical guide for the clinician. CMAJ 2006; 175: 265-275.
5. Hohmann A, Suplita R. Endocannabinoid mechanisms of pain modulation. AAPS J 2006; 8: E693-708.
6. Campbell FA, Tramer MR, Carroll D et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-16.
7. Klepstad P, Dale O, Borchgrevink PC et al. Genetic variation - important for the clinical effect of opioids? Tidsskr Nor Laegeforen 2005; 6: 2655-2658.
8. Rossa J, Rileya J, Quigleyc C et al. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 2006; 11: 765-773.
9. McCormick W, Schreiner R. Diagnosis and treatment of opiate-resistant pain in advanced AIDS West. J Med 2001; 175: 408-411.
10. Bouhassira D, Attal N, Alchaar H et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005; 114: 29-36.